WESTFORD, Mass., Sept. 24,
2014 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO), a leader
in laser- and light-based aesthetic treatments for non-invasive and
minimally invasive applications, today announced that it has
received FDA 510(k) clearance to market its flagship PicoSure
Picosecond Laser Workstation for the treatment of wrinkles with the
Company's new disposable energy delivery system, the FOCUS lens
array. In the fourth quarter of 2012, PicoSure became the
world's first picosecond device to receive FDA clearance for the
removal of tattoos and benign pigmented lesions.
"This clearance complements our recently received approval to
market PicoSure for the treatment of acne scars, and demonstrates
the breadth of our FOCUS lens array technology to address
additional high-volume indications," said Cynosure Chairman and
Chief Executive Officer Michael
Davin. "According to the independent industry research and
analysis firm Medical Insight, worldwide sales for skin
rejuvenation platforms are projected to grow at a compound annual
growth rate of 8.2 percent through 2018 to $512.6 million. We believe this large addressable
market represents a significant growth opportunity for Cynosure and
provides another avenue to drive our disposables revenue."
About Cynosure, Inc.
Cynosure develops and markets
aesthetic treatment systems that enable plastic surgeons,
dermatologists and other medical practitioners to perform
non-invasive and minimally invasive procedures to remove hair,
treat vascular and benign pigmented lesions, remove multi-colored
tattoos, revitalize the skin, liquefy and remove unwanted fat
through laser lipolysis, reduce cellulite, clear nails infected by
toe fungus and ablate sweat glands. Cynosure's product
portfolio is composed of a broad range of energy sources including
Alexandrite, diode, Nd: YAG, picosecond, pulse dye, Q-switched
lasers, intense pulsed light and radiofrequency technology.
Cynosure sells its products globally under the Cynosure, Palomar,
ConBio and Ellman brand names through a direct sales force in
the United States, Canada, Mexico, France, Germany, Spain, the United
Kingdom, Australia,
China, Japan and Korea, and through international
distributors in approximately 120 other countries. For
corporate or product information, visit Cynosure's website at
www.cynosure.com.
Forward-Looking Statements
Any statements in this
press release about Cynosure's receipt of FDA clearance to market
PicoSure for the treatment of wrinkles, as well as other statements
containing the words "believes," "anticipates," "plans," "expects,"
"will" and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including the market acceptance of PicoSure,
levels of demand for procedures performed with Cynosure products
and for Cynosure products themselves, competition in the aesthetic
laser industry, general business and economic conditions, effects
of acquisitions that Cynosure has made or may make, Cynosure's
ability to develop and commercialize new products, Cynosure's
reliance on sole source suppliers, the inability to accurately
predict the timing or outcome of regulatory decisions, and
economic, market, technological and other factors discussed in
Cynosure's most recent Annual Report on Form 10-K which is filed
with the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
Cynosure's views as of the date of this press release. Cynosure
anticipates that subsequent events and developments will cause its
views to change. However, although Cynosure may elect to update
these forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Cynosure's views as of any date subsequent to the date
of this press release.
Contact
Scott
Solomon
Vice President
Sharon Merrill Associates
617-542-5300
cyno@investorrelations.com
SOURCE Cynosure, Inc.